Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.
Jullien V, Tréluyer JM, Rey E, Jaffray P, Krivine A, Moachon L, Lillo-Le Louet A, Lescoat A, Dupin N, Salmon D, Pons G, Urien S. Jullien V, et al. Among authors: dupin n. Antimicrob Agents Chemother. 2005 Aug;49(8):3361-6. doi: 10.1128/AAC.49.8.3361-3366.2005. Antimicrob Agents Chemother. 2005. PMID: 16048948 Free PMC article.
High concentrations of nelfinavir as an independent risk factor for lipodystrophy in human immunodeficiency virus-infected patients.
Tréluyer JM, Morini JP, Dimet J, Gorin I, Rey E, Deleuze J, Ceccaldi PF, Escande JP, Pons G, Dupin N. Tréluyer JM, et al. Among authors: dupin n. Antimicrob Agents Chemother. 2002 Dec;46(12):4009-12. doi: 10.1128/AAC.46.12.4009-4012.2002. Antimicrob Agents Chemother. 2002. PMID: 12435713 Free PMC article. Clinical Trial.
Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M, Buffet M, Schwarzinger M, Roman P, Bui P, Prévot M, Deleuze J, Morini JP, Franck N, Gorin I, Dupin N. Burnouf M, et al. Among authors: dupin n. Arch Dermatol. 2005 Oct;141(10):1220-4. doi: 10.1001/archderm.141.10.1220. Arch Dermatol. 2005. PMID: 16230558 Clinical Trial.
A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.
Bouillon-Pichault M, Jullien V, Piketty C, Viard JP, Morini JP, Chhun S, Krivine A, Salmon D, Dupin N, Weiss L, Lortholary O, Pons G, Launay O, Treluyer JM. Bouillon-Pichault M, et al. Among authors: dupin n. Antivir Ther. 2009;14(7):923-9. doi: 10.3851/IMP1414. Antivir Ther. 2009. PMID: 19918096
Remission of severe CD8(+) cytotoxic T cell skin infiltrative disease in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy.
Sbidian E, Battistella M, Rivet J, Flageul B, Molina JM, Joly P, Caumes E, Gorochov G, Cayuela JM, Rabian C, Dupin N, Lebbé C, Janin A, Janier M, Oksenhendler E, Bachelez H. Sbidian E, et al. Among authors: dupin n. Clin Infect Dis. 2010 Sep 15;51(6):741-8. doi: 10.1086/655895. Clin Infect Dis. 2010. PMID: 20687841
479 results